ClinicalTrials.gg
RecruitingNCT05265429Updated Oct 19, 2026

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

An observational study in Non Small Cell Lung Cancer, Small Cell Lung Carcinoma and NUT Carcinoma, sponsored by Dana-Farber Cancer Institute. Recruiting at 4 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Dana-Farber Cancer Institute · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Oct 19, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Dana-Farber Cancer Institute.

Started
2023
the only one that year
Observational
Only one
of the 20
Registered
18th of 20
by date

Among the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, this one is the only one that started in 2023, is the only observational one, and was the 18th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

Read the detailed description

This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to:

  • Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease
  • Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger
  • Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients
  • Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger

Study procedures will include:

  • Collecting information from participants' medical record and two (2) short questionnaires
  • Collecting blood and/or saliva samples
  • Collecting tumor tissue samples (optional)

It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • NUT Carcinoma

Keywords

  • Non Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Genetics
  • Genomics
  • Young lung cancer
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults age 45 or under at time of non-small lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 45 and under at lung cancer diagnosis
  • confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
  • Provision of written
  • Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
  • Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion criteria

Exclusion Criteria:

  • Individuals who decline to sign consent
  • Individuals who are unable to give consent or assent and are without a designated healthcare proxy
  • Compromise of patient diagnosis or staging if tissue is used for research
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Data/Biospecimen Collection

    Tumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger

    Genetic: Data and Specimen Collection

Interventions

  • GeneticData and Specimen Collection

    * Provide research team access to relevant medical records * Answer two (2) short questionnaires at time of consent * Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample * Consider consenting to other optional parts of the research such as: * Providing additional blood or tissue samples in the future (optional) * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)

06

What researchers measure

Primary outcomes

  1. Repository of specimens and data

    Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.

    Time frame: 5 years or study closure

Secondary outcomes

  1. Number of patients with targetable somatic alterations in known oncogenic driver genes

    Targetable alterations are defined as any somatic alteration in a driver oncogene for which a Food and Drug Administration-approved therapy exists, for which an off-label therapy exists, or for which a clinical trial exists (including but not limited to EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, and TRK). Results will be summarized using descriptive statistics.

    Time frame: 5 years or study closure

  2. Number of patients with predicted oncogenic alterations in unknown driver genes

    Unknown driver genes include genes not currently known to be driver oncogenes in lung cancer, and for which no directed treatment exists. Results will be summarized using descriptive statistics.

    Time frame: 5 years or study closure

  3. Number of patients with pathogenic or likely pathogenic germline alterations in known cancer predisposition genes

    Pathogenic or likely pathogenic variants based on classification by the American College of Medical Genetics and Genomics (ACMG). Results will be summarized using descriptive statistics.

    Time frame: 5 years or study closure

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2027, 55 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 55 months is close to that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Mar 3, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: added J•••@dfci.harvard.edu · •••8041. See the current contact
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Contact Study contact changed: added J•••@dfci.harvard.edu · •••8041. See the current contact
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05265429
Responsible party
Jaclyn LoPiccolo, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Mar 3, 2022
Start date
Jan 1, 2023
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Jaclyn LoPiccolo, MD, PhD
Contact
Jaclyn_LoPiccolo@dfci.harvard.edu
857-215-8041
Pasi A Janne, MD, PhD
Contact
Pasi_Janne@dfci.harvard.edu
617-632-6036
Pasi A Janne, MD, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion